LEVELS OF SYSTEMIC INFLAMMATORY RESPONSE MARKERS IN PATIENTS WITH PULMONARY HYPERTENSION AND COPD
PDF

Keywords

markers of systemic inflammatory response, pulmonary hypertension, chronic obstructive pulmonary disease, mean pulmonary artery pressure

How to Cite

I. M. Fushtey, K. L. Nikolaieva, & E. V. Sid’. (2020). LEVELS OF SYSTEMIC INFLAMMATORY RESPONSE MARKERS IN PATIENTS WITH PULMONARY HYPERTENSION AND COPD. Eastern Ukrainian Medical Journal, 8(1), 84-90. https://doi.org/10.21272/eumj.2020;8(1):84-90

Abstract

Introduction. The prevalence of COPD worldwide is about 7.6 %, and it is one of the main causes of morbidity and mortality in today society. Today, much information has been obtained about the pathogenetic mechanisms of COPD development. However, more and more studies have recently shown that COPD patients have an increase in proinflammatory mediators that contribute to the development of systemic subclinical inflammation; this is due to the involvement of inflammatory cells from the bloodstream in the process, and the development of a systemic inflammatory response. An urgent medical and social problem of our time is the development of pulmonary hypertension in patients with COPD. The processes of inflammation and remodeling of the vascular wall are inseparable; they complement each other, leading to the formation of a clinical picture of pulmonary hypertension.

The aim of the study. To determine the levels of markers of systemic inflammatory response among patients with pulmonary hypertension on the background of COPD.

Materials and methods. The results of the study are based on data from a comprehensive survey of 170 patients aged 40 to 65 years with COPD, 123 of which had pulmonary hypertension and 47 ones had no PH.

Obtained results. The level of hs-CRP in the group of PH patients with COPD was 10.46 [6.24; 15.30] mg/l and was significantly higher, both against the value of 7.30 [6.22; 9.18] mg/l in the group of COPD patients without PH (p < 0.05), and in comparison with the group of healthy individuals, where this indicator was 1.08 [0.96; 1.41] mg/l, (p < 0.05). The increase in IL-6 levels was significantly higher by 57% in the group of PH patients with COPD compared to the value of 5.67 [4.44; 6.98] PG/ml, (p < 0.05) in the group of COPD without PH and amounted to 8.90 [7.76; 9.93] PG/ml, and a 7.4-fold increase in the value of 1.20 [0.95; 1.57] PG/ml in the group of healthy individuals, (p < 0.05). The median level of IL-10 was significantly higher in the group of healthy individuals by 11.2 % and 10 % compared to the groups of patients with PH on the background of COPD and COPD without PH, respectively, and was 5.35 [4.97; 6.86] PG/ml, (p < 0.05). In the groups of patients with PH on the background of COPD and COPD without PH, there was a significant increase in this indicator by 8.8 and 6 times compared to the level of 0.21 [0.20; 0.25] in the group of healthy individuals, (p < 0.05). Comparing subgroups of patients depending on the type of COPD exacerbation, the level of hs-CRP, IL-6 and the ratio of IL-6/IL-10 levels were significantly higher in the subgroup with infectious type of exacerbation compared to the subgroup of non-infectious type of COPD exacerbation, (p < 0.05).

https://doi.org/10.21272/eumj.2020;8(1):84-90
PDF

References

1. Dury R. COPD and emotional distress: not always noticed and therefore untreated. British journal of community nursing. 2016; 21(3): 138-141. DOI: 10.12968/bjcn.2016.21.3.138
2. Rodriguez-Roisin R, Rabe KF, Vestbo J, et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th anniversary: a brief history of time. European Respiratory Journal. 2017; 50: 1-6. DOI: 10.1183/13993003.00671-2017
3. Panahi Y, Jadidi-Niaragh F, Azimzadeh Jamalkandi S, et al. Immunology of chronic obstructive pulmonary disease and sulfur mustard induced airway injuries: implications for immunotherapeutic interventions. Current pharmaceutical design. 2016; 22(20): 2975-2996.
4. Sirenko YuM, Zhyvylo IO, Radchenko HD. Stvorennia zahalnoderzhavnoho reiestru khvorykh iz lehenevoiu hipertenziieiu - vymoha suchasnosti?. Ukrainskyi kardiolohichnyi zhurnal. 2016; 1: 41-46.
5. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circulation research. 2014; 115(1): 165-175. DOI:10.1161/CIRCRESAHA.113.301141
6. Hu J, Xu Q, McTiernan C, et al. Novel targets of drug treatment for pulmonary hypertension. American Journal of Cardiovascular Drugs. 2015; 15(4): 225-234. DOI:10.1007/s40256-015-0125-4
7. Morello Gearhart A, Cavallazzi R, Peyrani P, et al. Lung Cytokines and Systemic Inflammation in Patients with COPD. The University of Louisville Journal of Respiratory Infections. 2017; 1(4): 1-4. DOI:10.18297/jri/vol1/iss4/4
8. Ardestani ME, Zaerin O. Role of serum interleukin 6, albumin and C-reactive protein in COPD patients. Tanaffos. 2015; 14(2): 134.
9. Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006; 130(2): 326-333. DOI: 10.1378/chest.130.2.326
10. Chaouat, A., Savale, L., Chouaid, C., et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009; 136(3): 678-687. DOI:10.1378/chest.08-2420
11. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010; 65(10): 930-936. DOI:10.1136/thx.2009.130260
12. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Annals of medicine. 2013; 45(3): 291-300. DOI:10.3109/07853890.2012.732703
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.